G1 Therapeutics' Trilaciclib Wins FDA Nod For Mitigating Chemo Effects In Lung Cancer Patients

by Vandana Singh, Benzinga Editor

February 16, 2021 4:37 AM | 1 min read |

G1 Therapeutics Inc (NASDAQ: GTHX) shares gain premarket after FDA approves COSELA (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression (damage to bone marrow) in adult patients when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small-cell lung cancer.
COSELA is administered intravenously as a 30-minute infusion within four hours before the start of chemotherapy. It is expected to be commercially available in early March.
G1 intends to initiate the post-approval clinical trial in 2022.
The management will host a webcast and conference call at 8:00 a.m. ET today.
Price Action: GTHX shares increased 36.5% at $42.18 in premarket trading on the last check Tuesday.

Posted In:

Biotech News Small Cap FDA General chemotherapy lung cancer

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.